Immuno-Oncology | Specialty

Dr. Brahmer on Impact of CheckMate-057 in NSCLC

June 11th 2015

Julie R. Brahmer, MD, interim director, Sidney Kimmel Comprehensive Cancer Center, associate professor of oncology, Johns Hopkins Medicine, discusses how the CheckMate-057 trial could impact the treatment of non-small cell lung cancer (NSCLC).

Wolchok Discusses Frontline Nivolumab/Ipilimumab Combo in Melanoma

June 10th 2015

Jedd D. Wolchok, MD, discusses the unique design and goals of the CheckMate-067 trial, and what its results mean for patients with advanced melanoma going forward.

Abiraterone Delays Time to First Opiate Use in mCRPC

June 5th 2015

Clinical Trials for Non-Metastatic CRPC

June 5th 2015

Evolving Role of Docetaxel in Metastatic Prostate Cancer

June 5th 2015

Clinical Trial Challenges in Metastatic CRPC

June 5th 2015

COU-AA-302: Abiraterone in Pre-Chemo CRPC

June 5th 2015

Role of AR-V7 in Multidisciplinary Prostate Cancer Care

June 5th 2015

CD19-Targeted CAR T-Cell Therapy Shows Promise in Multiple Myeloma

June 5th 2015

The CD19-targeted chimeric antigen receptor T-cell therapy CTL019 demonstrated early evidence of activity and safety in patients with refractory multiple myeloma.

FDA Grants Priority Review to Pembrolizumab in Lung Cancer

June 2nd 2015

The FDA has assigned a priority review designation to the PD-1 inhibitor pembrolizumab as a treatment for patients with advanced NSCLC across all histologies whose disease has progressed on or after platinum-containing chemotherapy, as well as a targeted agent in EGFR- or ALK-positive patients.

Dr. Socinski on Nivolumab in NSCLC

June 2nd 2015

Mark A. Socinski, MD, professor of Medicine and Cardiothoracic Surgery, director, Lung Cancer Section, Division of Hematology/Oncology, clinical associate director, Lung SPORE, co-director, UPMC Lung Cancer Center of Excellence, co-leader, UPCI Lung Cancer Program, discusses a phase III study which examined nivolumab in non-small cell lung cancer (NSCLC).

Dr. Spira on Atezolizumab in the POPLAR Study for NSCLC

June 2nd 2015

Alexander Spira, MD, PhD, FACP, medical oncology, hematology, Virginia Cancer Specialists, discusses the POPLAR study for non-small cell lung cancer (NSCLC).

Frontline Nivolumab Regimens Significantly Improve PFS Versus Ipilimumab in Melanoma

May 31st 2015

Frontline nivolumab as monotherapy and in combination with ipilimumab more than doubled progression-free survival versus ipilimumab alone in patients with advanced melanoma.

Atezolizumab Doubles OS in PD-L1-Positive NSCLC

May 31st 2015

Treatment with atezolizumab doubled overall survival compared with docetaxel in previously treated patients with PD-L1-positive squamous and non-squamous non-small cell lung cancer.

MEDI4736, Tremelimumab Combo Active in Pretreated NSCLC

May 31st 2015

An immunotherapy combination demonstrated "high levels of clinical activity" in previously treated non-small cell lung cancer across a range of doses.

Phase III Data Show Nivolumab Improves Survival Across Lung Cancer Subtypes

May 29th 2015

Nivolumab has now been shown to have an overall survival benefit versus docetaxel in both nonsquamous and squamous non–small cell lung cancer.

Dr. Seiwert on Pembrolizumab in Head and Neck Cancer

May 29th 2015

Tanguy Seiwert, MD, assistant professor of medicine and associate leader of the head and neck cancer program, University of Chicago, discusses the efficacy of pembrolizumab in head and neck cancer.

Pembrolizumab Demonstrates "Remarkable Efficacy" in Advanced HNSCC

May 29th 2015

In a multisite study offering the largest experience to date of how immunotherapy can be deployed in patients with head and neck cancer, the anti-PD-1 antibody pembrolizumab produced broad and durable responses in patients with advanced disease.

Mismatch Repair a Potential Biomarker for PD-1 Inhibition

May 29th 2015

Treatment with the PD-1 inhibitor pembrolizumab demonstrated high response rates in patients with heavily pretreated colorectal cancer who harbored genetic defects in mismatch repair.

Dr. Burris on the Impact of the ASCO Annual Meeting

May 28th 2015

Howard Burris, III, MD, chief medical officer and executive director of Drug Development at the Sarah Cannon Research Institute discusses the importance of the ASCO annual meeting, taking place May 29 - June 2.